| Carcinoma | Cell lines | Effects | References |
| Multiple myeloma | MM.1S, MM.1R, Dox40, MR20, LR5, RPMI8226, IM-9, U266, ARH-77, Hs Sultan | IkBa degradation, inhibited IL-6-triggered activation of p42/44 MAPK as well as TNF-a induced activation of NF-κB, | Hideshima et al., 2001 [7] |
| Mantle cell lymphoma | Mino, DB (sp53), Molt-4, L-428 | NF-κB activation, bcl-xL and bfl/A1 inhibition, and bcl-2 cleavage | Pham et al., 2003 [8] |
| NSCLC | H460, H322, H358, H157, A549 | Cell cycle arrest at G2-M; Bcl-2 phosphorylation and cleavage; p53 stabilization; induction of p21Cip; increase in cyclins A and B; activation of CDKs; mitochondrial cytochrome c release; activation of caspase pathway; apoptosis; NF-κB Downregulation | Ling et al., 2002 [9], 2003 [10], and 2003 [11]; Denlinger et al., 2004 [12] |
| Prostate | PC-3 (p53 null) | Cell cycle arrest at G2-M; increase in p21Cip; inhibition of CDK4 activity; PARP cleavage; apoptosis | Adams et al., 1999 [13] | LNCaP-Pro5 | Activation of caspase-3; apoptosis | Williams et al., 2003 [14] |
| Pancreatic | MIA-PaCa-2 | Enhanced cytotoxic effects of gemcitabine; reduced NF-κB activation; reduced Bcl-2 expression without affecting Bax or Bak; PARP cleavage; apoptosis | Bold et al., 2001 [15] | BxPC3 | Cell cycle arrest in G0–G1; increase in p21Cip; caspase-3 activation; apoptosis | Shah et al., 2001 [16] |
| SCCHN | UM-SCC-9, UM-SCC-11B | Cell cycle arrest in G2-M and S phases; increase in p21Cip; apoptosis; (PARP cleavage shown in murine SCCHN lines); NF-κB Downregulation | Sunwoo et al., 2001 [17] |
| Ovarian | SKOV 3 | Induction of p21Cip; inactivation of Bcl-xL; Downregulation of XIAP; PARP cleavage; activation of caspase pathway; apoptosis | Frankel et al., 2000 [18] |
| Breast | MCF-7 | Cytotoxicity (molecular markers not determined) | Teicher et al., 1999 [19] |
| Colorectal | LOVO, KM12L4, WiDR | Inhibits chemotherapy-induced NF-κB activation; enhances chemotherapy-induced apoptosis; stabilizes p53, p21Cip; p27Kip | Cusack Jr. et al., 2001 [20] |
|
|